Xinnate raises SEK 14.5 million for clinical study of wound gel

Helene Hartman, CEO of Xinnate

Startup company Xinnate has obtained promising results in preclinical studies and is now preparing to conduct a clinical study in the second half of 2021 for its first product, BioC wound gel, for the treatment of acute wounds. The gel is based on a completely new approach to wound healing through endogenous mechanisms. To finance the study, Xinnate raised SEK 14.5 million for the company through a rights issue.

Life-threatening complications from wounds are a major and growing global problem, both because current methods are inadequate and because antibiotics, today's lifeline, do not always work due to the development of multi-resistant bacteria.

Xinnate and a group of researchers in Lund have collaborated to develop the wound gel, which has been shown in animal studies to be significantly more effective than conventional therapies. Professor Artur Schmidtchen, co-founder of Xinnate, and his team at Lund University have extensively studied natural endogenous mechanisms and substances that are involved in our normal wound healing. They have shown that the gel is effective at both preventing and treating infections in wounds. 

“The purpose of this initial clinical study is to show that the product is safe, while providing us with the opportunity to study the antibacterial effect of the product, as well as its highly interesting anti-inflammatory properties, which together make the wound gel unique and explain the good wound healing results we have seen to date during in vivo testing,” says Helene Hartman, CEO of Xinnate.

Xinnate is a member company of SmiLe Incubator, a business incubator for life science companies located in Medicon Village in Lund, Sweden.  

 For information about the product please contact: Helene Hartman, CEO, Xinnate,  +46 (0)725-120312,  helene.hartman@xinnate.com

 About Xinnate:
Xinnate focuses on developing pharmaceutical concepts for external applications in skin and wound care, surgery and biomaterials. The company develops products based on one of our natural defense mechanisms that has been shown to have a unique and sustainable anti-inflammatory and antibacterial effect regardless of multi-resistance.  Xinnate is a member of SmiLe Incubator, a business incubator located in Medicon Village in Lund, Sweden, and is a subsidiary of in2cure. www.Xinnate.com